Physician profile
Dave Chawla
NPI 1275790149
$395.39
in general payments reported to CMS, 2019-2025
11 companies · $63.23 in 2025
The $63.23 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.64 · 2020: $170 · 2021: $54.75 · 2022: $19.47 · 2023: $38.72 · 2024: $24.32 · 2025: $63.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $126.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $91.52 | 2019-2020 | |
| Heartflow, INC. | $75.79 | 2023-2025 | Ffrct |
| Esperion Therapeutics, INC. | $42.39 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $35.70 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $33.77 | 2020-2021 | |
| Boston Scientific Corporation | $26.16 | 2025 | Farapulse |
| Inspire Medical Systems, INC. | $24.32 | 2024 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.43 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $18.79 | 2020 | |
| Novo Nordisk INC | $13.18 | 2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dave Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.